Genetic Testing in SMA

Video

Tim Hagenacker, MD: Genetic testing is the basis of diagnosis for type 2 SMA [spinal muscular atrophy]. In the years before drugs like nusinersen were available, genetic testing was not performed in every case, especially when patients had a long-term diagnosis. At that time, genetic testing had no consequence on treatment. Often, a diagnosis was made by symptoms, in addition to some electrophysiologic diagnostics. Now that treatment is available, we need the confirmation that it’s really a 5q SMA.

The classical test is the multiplex ligation-dependent probe amplification, or MLPA, to detect the deletion of the SMN gene, and to detect the copy number of the SMN2 gene. Besides that, a classical test can also be performed from a dried-spot blood test. Those are the common tests available.

In most cases, you have homozygous deletion of the SMN1 gene, but there are a few cases that are compound heterozygous. We have a deletion on 1 allele of the SMN1 gene and a point mutation on the other allele. The SMN2 copy number determines the severity of the disease. There is a good correlation between increasing copy number and a less severely impaired patient. Typically you have, for example, 2 SMN2 copies in an SMA type 2 patient, and 4 SMN2 copies in an SMA type 3 patient. This is a correlation in approximately 80% to 90%. There are also other patients in which you don’t have that correlation. We possibly have some other genetic modifiers.


Related Videos
Kevin Church, PhD
Merit Cudkowicz, MD, MSc
Jessica Ailani, MD
Frederic Schaper, MD, PhD
Jaime Imitol, MD
Jason M. Davies, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.